List of Excipients in Branded Drug ZYTIGA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	CELLULOSE, MICROCRYSTALLINE
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	CROSCARMELLOSE SODIUM
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	LACTOSE MONOHYDRATE
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	MAGNESIUM STEARATE
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	POVIDONE
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	SILICON DIOXIDE
Janssen Biotech Inc	ZYTIGA	abiraterone acetate	57894-150	SODIUM LAURYL SULFATE

Zytiga Excipient Strategy and Commercial Opportunities for Abiraterone Acetate

Last updated: August 9, 2026

Zytiga is an oral abiraterone acetate product whose commercial weakness is driven by poor aqueous solubility, strong food effect, and generic competition. The reference formulation uses a conventional immediate-release tablet with lactose, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate and, in the 250 mg product, colloidal silicon dioxide. The strongest current opportunities are generic cost reduction, low-dose or lower-pill-burden products, food-effect mitigation, pediatric or special-population formulations, and differentiated delivery systems.

What is Zytiga and which active ingredient does it contain?

Zytiga contains abiraterone acetate, a prodrug converted in vivo to abiraterone. Abiraterone inhibits CYP17, reducing androgen production in the testes, adrenal glands and prostate tumor tissue. The product is approved with prednisone or prednisolone for advanced prostate cancer, including metastatic castration-resistant prostate cancer and, in certain markets, metastatic high-risk castration-sensitive disease.

Attribute	Zytiga reference product
Active ingredient	Abiraterone acetate
Dosage forms	Immediate-release tablets
Strengths	250 mg and 500 mg
Route	Oral
Reference holder	Janssen Biotech / Johnson & Johnson
Administration	On an empty stomach
Typical adult dose	1,000 mg once daily with corticosteroid therapy
Main formulation issue	Very low aqueous solubility and pronounced food effect
Main generic pathway	FDA ANDA, subject to pharmaceutical equivalence and bioequivalence

The empty-stomach requirement is commercially important. A high-fat meal substantially increases abiraterone exposure, creating risks of excessive pharmacologic effect and toxicity if dosing instructions are not followed [1].

What excipients are used in Zytiga tablets?

The US reference formulation uses standard direct-compression or wet-granulation excipient classes rather than a proprietary delivery platform. The FDA label identifies the following core excipients [1]:

Excipient	Functional role	Commercial relevance
Lactose monohydrate	Diluent and tablet mass former	Low cost, broad supply base; limits use in lactose-intolerant populations only in selected cases
Microcrystalline cellulose	Diluent, compressibility aid	High-volume commodity excipient with multiple supplier options
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet breakup and dissolution
Povidone	Binder and granulation aid	Controls granule strength and manufacturability
Sodium lauryl sulfate	Wetting and dissolution aid	Particularly relevant to poorly soluble abiraterone acetate
Magnesium stearate	Lubricant	Can reduce dissolution if over-lubrication occurs
Colloidal silicon dioxide	Glidant and flow aid	Listed for the 250 mg presentation
Film-coating materials	Appearance, protection and swallowability	Includes polymer, plasticizer, pigment and opacifying components

The 250 mg and 500 mg tablets do not have identical listed excipient compositions. The 500 mg tablet is intended to reduce tablet count for the standard 1,000 mg daily dose. Formulators should assess each strength as a separate product because compression force, tablet weight, dissolution, coating performance and impurity behavior can differ.

How does abiraterone acetate’s solubility affect excipient selection?

Abiraterone acetate is a poorly water-soluble compound. The reference formulation therefore relies on particle wetting, rapid disintegration and efficient gastrointestinal dissolution rather than on a high-solubility drug substance.

The main excipient levers are:

1. Wetting enhancement through sodium lauryl sulfate or an alternative surfactant.
2. Rapid disintegration through croscarmellose sodium or another superdisintegrant.
3. Particle-size control or micronization of abiraterone acetate.
4. Granulation and compression optimization to prevent hard, slowly disintegrating tablets.
5. Lubricant control to avoid dissolution suppression.
6. Film-coating selection that does not delay release.

A generic manufacturer can often obtain acceptable bioequivalence with a conventional formulation, but the formulation must reproduce the reference product’s exposure profile. Dissolution similarity alone is insufficient where the drug has low solubility, high variability or a clinically relevant food effect.

Which excipient substitutions are commercially practical?

The most practical substitutions involve established, compendial materials:

• Lactose monohydrate can be replaced with mannitol, anhydrous lactose, dibasic calcium phosphate or selected grades of microcrystalline cellulose.
• Sodium lauryl sulfate can be replaced or supplemented with poloxamers, sodium docusate or other wetting agents, subject to safety and performance evaluation.
• Croscarmellose sodium can be replaced with crospovidone or sodium starch glycolate.
• Povidone can be replaced with copovidone, hydroxypropyl cellulose or other binders.
• Colloidal silicon dioxide can be replaced with a different glidant system or optimized through particle engineering.

The strongest substitution opportunities are those that improve dissolution without creating a new regulatory burden. A formulation that requires a novel excipient, unusually high surfactant loading or a new route of administration has a longer development path and greater regulatory risk.

What formulation patents protect Zytiga and abiraterone acetate?

The commercial value of Zytiga’s original formulation patents has largely declined because the principal US product and method-of-use exclusivities have expired or have been overtaken by approved generic competition. The original abiraterone acetate patent estate included composition-of-matter and therapeutic-use protection associated with abiraterone and its acetate prodrug. Patent protection varied by jurisdiction and claim type.

The relevant patent categories are:

Patent category	Protected subject matter	Current commercial significance
Composition of matter	Abiraterone and abiraterone acetate compounds	Historical foundation of Zytiga exclusivity
Pharmaceutical compositions	Tablets, excipient systems and dosage forms	Potentially relevant to later generic or differentiated products
Method of use	Treatment of prostate cancer with abiraterone acetate plus corticosteroid	Some claims may have influenced generic launch timing
Crystalline or solid-state forms	Polymorphs, salts and solid formulations	Relevant where a specific form improves stability or manufacturability
Manufacturing processes	Synthesis, purification and crystallization	Important for API cost and freedom to operate
Combination therapy	Abiraterone with prednisone or related corticosteroids	Primarily historical or jurisdiction-specific

The US Orange Book has been the principal source for listed Zytiga patents and exclusivity information [2]. Because Orange Book listings and litigation records can change, a live freedom-to-operate analysis must review the current FDA listing, patent family status and jurisdiction-specific prosecution history rather than rely on the original Zytiga label alone.

When did Zytiga lose exclusivity and when did generic entry begin?

Generic abiraterone acetate entered the US market after patent litigation and settlement activity involving Janssen and generic applicants. FDA-approved generic versions are now commercially available, meaning the market has moved from originator exclusivity to price competition and product differentiation [3].

Event	Commercial effect
Original Zytiga approval	Established abiraterone acetate as an oral androgen-synthesis inhibitor
Orange Book patent litigation	Delayed or structured generic entry for some applicants
Generic approvals	Shifted competition toward price, supply reliability and formulation execution
Current market	Multiple generic manufacturers and distributor-led substitution

The exact launch date and authorized-generic status can differ by country and by manufacturer. In the United States, generic products are generally dispensed through substitution rules governed by state law and payer policy.

Which companies are challenging or competing with Zytiga?

The competitive field includes generic abiraterone acetate manufacturers, branded androgen-receptor pathway inhibitors and other prostate-cancer therapies.

Segment	Examples	Competitive effect
Generic abiraterone	Multiple ANDA sponsors	Price erosion and procurement competition
Branded androgen-signaling drugs	Xtandi, Erleada, Nubeqa	Compete for treatment positioning and payer budgets
Chemotherapy	Docetaxel and cabazitaxel	Alternative systemic treatment
Radiopharmaceuticals	Lutetium-177-based therapies in eligible patients	Compete in later-line disease
Emerging hormonal agents	Next-generation androgen-axis products	May reduce reliance on abiraterone in selected patients

Abiraterone retains a cost advantage in many markets because generic tablets are inexpensive relative to newer branded agents. That advantage supports continued demand but limits pricing power for a new conventional tablet.

What commercial opportunities exist in Zytiga excipients?

1. Lower-cost generic tablets

The highest-probability opportunity is an optimized generic tablet using widely available excipients and a robust manufacturing process. Value can come from:

• Lower tablet weight.
• Reduced dependence on sodium lauryl sulfate.
• Improved flow and compression.
• Shorter granulation cycle.
• Lower coating-material consumption.
• Reduced rejection rates from dissolution or content-uniformity failures.

This is an operational opportunity rather than a premium-price opportunity.

2. Reduced pill burden

The standard 1,000 mg dose requires either two 500 mg tablets or four 250 mg tablets. A higher-strength tablet, bilayer tablet or alternative dosage form could reduce pill burden, but it would require new bioequivalence and stability work. A 1,000 mg single tablet may create practical problems involving tablet size, dose uniformity, swallowability and mechanical strength.

3. Food-effect mitigation

A formulation that delivers consistent exposure with food or reduces the magnitude of the food effect has the greatest clinical differentiation potential. Potential technologies include:

• Amorphous solid dispersions.
• Lipid-based formulations.
• Self-emulsifying drug-delivery systems.
• Nanocrystals.
• Spray-dried dispersions.
• Supersaturating formulations.
• Modified-release systems.

These products would likely require a 505(b)(2) application or equivalent non-generic pathway in the United States if they materially differ from the reference product. The commercial value would depend on whether the product can demonstrate safer, simpler or more reliable dosing.

4. Lactose-free or excipient-reduced formulations

A lactose-free formulation could address a narrow patient segment, but lactose in the reference tablet is not generally a major clinical barrier at the quantities used. The business case is stronger when lactose removal also improves manufacturability, reduces moisture sensitivity or supports a clean-label positioning in selected international markets.

5. Hospital and specialty-pharmacy supply

Contract manufacturers and specialty distributors can compete through:

• Reliable API sourcing.
• Dual excipient suppliers.
• Regional packaging.
• Smaller minimum order quantities.
• Stable supply of both 250 mg and 500 mg strengths.
• Serialization and cold-chain-free logistics.

Abiraterone tablets generally do not require cold-chain distribution, making manufacturing scale, inventory control and regulatory reliability central competitive factors.

How strong is the patent estate for a new abiraterone formulation?

A new formulation can have meaningful patent value only if it produces a defensible technical result. Merely replacing lactose with mannitol or changing a superdisintegrant will usually face a narrow inventive-step argument unless the change delivers an unexpected dissolution, stability, exposure or food-effect result.

The strongest patent positions are likely to involve:

• A defined amorphous form with controlled physical stability.
• A particle-size distribution linked to improved exposure.
• A specific surfactant-polymer ratio.
• A food-independent exposure profile.
• A formulation that reduces dose or tablet count.
• A manufacturing process that consistently produces a protected solid form.
• A new dosage form for patients unable to swallow conventional tablets.

Patent claims should be drafted across composition, process, use and performance parameters. A single excipient list is usually weaker than a formulation claim tied to measurable dissolution or pharmacokinetic performance.

What FDA regulatory pathway applies to a new Zytiga product?

A conventional tablet that is pharmaceutically equivalent to Zytiga can generally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must address active ingredient, strength, dosage form, route, labeling, quality and bioequivalence requirements [4].

A materially different formulation may require a 505(b)(2) application. This pathway is more appropriate where the product changes:

• Administration with food.
• Release profile.
• Dosage form.
• Dose strength.
• Route of administration.
• Excipients in a way that affects clinical performance.
• Patient population or therapeutic use.

The FDA’s product-specific guidance for abiraterone acetate should be reviewed for dissolution, fed and fasting studies, strength waivers and other bioequivalence expectations [5].

What generic launch risks exist for abiraterone acetate?

The principal risks are technical and commercial:

Risk	Business consequence
Food-effect mismatch	Failed or delayed bioequivalence program
Slow dissolution	Exposure variability and regulatory deficiency
API polymorph variation	Stability and performance failures
Over-lubrication	Reduced dissolution and batch rejection
Surfactant incompatibility	Stability, impurity or tolerability problems
Large tablet size	Poor adherence and product complaints
Generic price erosion	Limited return on conventional formulation investment
Supplier concentration	Shortages or manufacturing interruptions
Patent-family overlap	Litigation or delayed launch in selected markets

Manufacturing IP can be more important than formulation IP. A low-cost, reproducible API process, protected solid-state form and reliable excipient supply may produce greater commercial value than a marginal tablet innovation.

How does Zytiga compare with competing prostate-cancer drugs?

Zytiga’s principal commercial advantage is generic affordability. Its disadvantages are the fasting requirement, corticosteroid coadministration, mineralocorticoid-related adverse effects and the need for continued laboratory monitoring.

Product	Key formulation or use advantage	Commercial limitation
Generic abiraterone	Low acquisition cost	Food restriction and prednisone requirement
Xtandi	No corticosteroid requirement in many uses	Higher branded cost
Erleada	Oral androgen-receptor inhibitor	Branded pricing and drug-interaction considerations
Nubeqa	Oral androgen-receptor inhibitor with differentiated clinical profile	Branded pricing
Docetaxel	Established intravenous chemotherapy	Infusion and systemic toxicity
Radioligand therapies	Targeted treatment for eligible patients	Specialized infrastructure and patient selection

A new abiraterone excipient platform must therefore deliver a clear advantage over a low-cost generic, not only over branded Zytiga.

Key Takeaways

• Zytiga contains abiraterone acetate in immediate-release tablets.
• The reference excipient system uses lactose, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate and magnesium stearate, with formulation differences between strengths.
• The central formulation problem is poor solubility combined with a strong food effect.
• Generic manufacturers have the clearest near-term opportunity through cost, supply reliability and manufacturing efficiency.
• Premium opportunities require food-effect mitigation, reduced pill burden, improved dissolution or a new delivery system.
• A conventional excipient substitution usually has limited patent strength unless linked to unexpected performance.
• ANDA is appropriate for equivalent generic tablets; materially differentiated products may require a 505(b)(2) pathway.
• API solid-state control, process economics and supply continuity are major barriers alongside excipient selection.
• Zytiga’s original patent estate has limited value against the current US generic market, but jurisdiction-specific patents and formulation families still require review.

FAQs about Zytiga excipient strategy

Can sodium lauryl sulfate be removed from an abiraterone tablet?

Yes, but removal can materially change wetting and dissolution. The replacement system must demonstrate equivalent or superior performance and support bioequivalence.

Is a lactose-free abiraterone tablet commercially attractive?

It can address a limited patient segment, but lactose removal alone is unlikely to support premium pricing. The opportunity improves if the change also increases stability or simplifies manufacturing.

Can a company market a 1,000 mg single abiraterone tablet?

Potentially, but the product would need to address tablet size, dose uniformity, mechanical strength, dissolution and bioequivalence. A new strength may require a regulatory pathway beyond a standard ANDA.

Are abiraterone excipients themselves patentable?

Individual established excipients generally are not strong standalone assets. Patent value is more likely in a defined combination, ratio, solid-state system, manufacturing process or performance-linked formulation.

Does a generic abiraterone product need to reproduce Zytiga’s exact excipient list?

No. An ANDA product generally may use different inactive ingredients if it satisfies applicable safety, quality, labeling and bioequivalence requirements.

References

1. U.S. Food and Drug Administration. (2023). Zytiga (abiraterone acetate) tablets: Prescribing information. Janssen Biotech, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. Abiraterone acetate product records. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2014). ANDA submissions: Content and format of abbreviated new drug applications. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Product-specific guidance for generic drug development: Abiraterone acetate tablets. Center for Drug Evaluation and Research.